{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:15:09Z","timestamp":1790252109096,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.bcp.2024.116408","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T20:22:52Z","timestamp":1720038172000},"page":"116408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K"],"prefix":"10.1016","volume":"226","author":[{"given":"Rong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2024.116408_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2021.0459","article-title":"Breast cancer: presentation, investigation and management","volume":"83","author":"Katsura","year":"2022","journal-title":"Br. J. Hosp. Med."},{"key":"10.1016\/j.bcp.2024.116408_b0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"9","key":"10.1016\/j.bcp.2024.116408_b0015","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","article-title":"Subtypes of breast cancer show preferential site of relapse","volume":"68","author":"Smid","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2024.116408_b0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/1871520616666160502122724","article-title":"Breast cancer: current molecular therapeutic targets and new players","volume":"17","author":"Nagini","year":"2017","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.bcp.2024.116408_b0025","doi-asserted-by":"crossref","unstructured":"A. Bergin, S. Loi, Triple-negative breast cancer: recent treatment advances. F1000Res, (2019) 8.","DOI":"10.12688\/f1000research.18888.1"},{"issue":"2","key":"10.1016\/j.bcp.2024.116408_b0030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.bcp.2024.116408_b0035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","article-title":"PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations","volume":"30","author":"Janku","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116408_b0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","volume":"48","author":"O'Donnell","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2024.116408_b0045","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR signaling in cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2024.116408_b0050","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.drudis.2019.09.001","article-title":"PI3K\/AKT\/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges","volume":"24","author":"Khan","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.bcp.2024.116408_b0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: the path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116408_b0060","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bcp.2024.116408_b0065","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1758834014530023","article-title":"The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers","volume":"6","author":"Paplomata","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2024.116408_b0070","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/bjc.2011.452","article-title":"E\/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma","volume":"105","author":"Araki","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2024.116408_b0075","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2024.116408_b0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1039\/C8RA08872A","article-title":"miR-425 suppresses EMT and the development of TNBC (triple-negative breast cancer) by targeting the TGF-beta 1\/SMAD 3 signaling pathway","volume":"9","author":"Liu","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.bcp.2024.116408_b0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.biopha.2016.03.010","article-title":"The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment","volume":"80","author":"Li","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"18","key":"10.1016\/j.bcp.2024.116408_b0090","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1158\/1078-0432.CCR-05-2722","article-title":"Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition","volume":"12","author":"Lee","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2024.116408_b0095","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ceb.2005.08.001","article-title":"Molecular requirements for epithelial-mesenchymal transition during tumor progression","volume":"17","author":"Huber","year":"2005","journal-title":"Curr. Opin. Cell Biol."},{"issue":"47","key":"10.1016\/j.bcp.2024.116408_b0100","doi-asserted-by":"crossref","first-page":"36803","DOI":"10.1074\/jbc.M005912200","article-title":"Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration","volume":"275","author":"Bakin","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116408_b0105","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/546353","article-title":"alpha-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K\/Akt pathway","volume":"2014","author":"Xu","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.bcp.2024.116408_b0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.podrm.2021.10.003","article-title":"Ticagrelor","volume":"47","author":"Kabil","year":"2022","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116408_b0115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.31083\/j.rcm2202044","article-title":"Ticagrelor: clinical development and future potential","volume":"22","author":"Sanderson","year":"2021","journal-title":"Rev. Cardiovasc. Med."},{"issue":"18","key":"10.1016\/j.bcp.2024.116408_b0120","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41388-018-0674-5","article-title":"B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells","volume":"38","author":"Zhou","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2024.116408_b0125","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1021\/acs.jmedchem.0c01652","article-title":"Structure-based drug design and synthesis of PI3Kalpha-selective inhibitor (PF-06843195)","volume":"64","author":"Cheng","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2024.116408_b0130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.molcel.2010.02.031","article-title":"The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration","volume":"38","author":"Chin","year":"2010","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.bcp.2024.116408_b0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4161\/cam.5.3.15790","article-title":"Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin","volume":"5","author":"Chin","year":"2011","journal-title":"Cell Adh. Migr."},{"issue":"1","key":"10.1016\/j.bcp.2024.116408_b0140","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1006\/excr.1999.4566","article-title":"The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin","volume":"251","author":"Guvakova","year":"1999","journal-title":"Exp. Cell Res."},{"issue":"15","key":"10.1016\/j.bcp.2024.116408_b0145","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/CIRCULATIONAHA.120.048770","volume":"142","author":"Franchi","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2024.116408_b0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-019-0700-2","article-title":"SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2024.116408_b0155","doi-asserted-by":"crossref","first-page":"6384278","DOI":"10.1155\/2019\/6384278","article-title":"Calcitriol inhibits the proliferation of triple-negative breast cancer cells through a mechanism involving the proinflammatory cytokines IL-1beta and TNF-alpha","volume":"2019","author":"Martinez-Reza","year":"2019","journal-title":"J. Immunol. Res."},{"issue":"5","key":"10.1016\/j.bcp.2024.116408_b0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12032-022-01675-2","article-title":"PIM1\/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer","volume":"39","author":"Mahata","year":"2022","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116408_b0165","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/13543784.2022.2049232","article-title":"Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer","volume":"31","author":"Agostinetto","year":"2022","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"11","key":"10.1016\/j.bcp.2024.116408_b0170","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11864-019-0682-x","article-title":"Targeted therapies for triple-negative breast cancer","volume":"20","author":"Lyons","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116408_b0175","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: Current and future perspectives (Review)","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"37","key":"10.1016\/j.bcp.2024.116408_b0180","doi-asserted-by":"crossref","first-page":"60712","DOI":"10.18632\/oncotarget.10858","article-title":"Triple negative breast cancer: shedding light onto the role of pi3k\/akt\/mtor pathway","volume":"7","author":"Massihnia","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.bcp.2024.116408_b0185","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdv163","article-title":"Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer","volume":"26","author":"Moulder","year":"2015","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116408_b0190","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006255","article-title":"PIK3CA copy-number gain and inhibitors of the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer","volume":"9","author":"Amato","year":"2023","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"issue":"10","key":"10.1016\/j.bcp.2024.116408_b0195","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1182\/blood-2017-02-769893","article-title":"Role of ADP receptors on platelets in the growth of ovarian cancer","volume":"130","author":"Cho","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2024.116408_b0200","doi-asserted-by":"crossref","unstructured":"O. Elaskalani, A. Domenichini, R.N. Abdol, E.D. D, M. Falasca, P. Metharom, Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT pathway in pancreatic cancer cells. Cancers (Basel), 12(1) (2020).","DOI":"10.3390\/cancers12010250"},{"issue":"1","key":"10.1016\/j.bcp.2024.116408_b0205","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ijc.28947","article-title":"The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer","volume":"136","author":"Gebremeskel","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2024.116408_b0210","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/ATVBAHA.114.303413","article-title":"Current state and novel approaches of antiplatelet therapy","volume":"35","author":"Metharom","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116408_b0215","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/1874467214666210204212533","article-title":"Ticagrelor ameliorates bleomycin-induced pulmonary fibrosis in rats by the inhibition of TGF-beta1\/Smad3 and PI3K\/AKT\/mTOR pathways","volume":"15","author":"Wanas","year":"2022","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116408_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111718","article-title":"Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer","volume":"183","author":"Elmenier","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116408_b0225","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijdevneu.2014.03.006","article-title":"Dysregulation of the IGF-I\/PI3K\/AKT\/mTOR signaling pathway in autism spectrum disorders","volume":"35","author":"Chen","year":"2014","journal-title":"Int. J. Dev. Neurosci."},{"issue":"6","key":"10.1016\/j.bcp.2024.116408_b0230","doi-asserted-by":"crossref","first-page":"670","DOI":"10.6004\/jnccn.2013.0086","article-title":"The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer","volume":"11","author":"Lauring","year":"2013","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.bcp.2024.116408_b0235","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4161\/cam.28024","article-title":"Palladin regulation of the actin structures needed for cancer invasion","volume":"8","author":"Najm","year":"2014","journal-title":"Cell Adhes. Migr."},{"issue":"2","key":"10.1016\/j.bcp.2024.116408_b0240","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.2013.757303","article-title":"Ticagrelor: the first novel reversible P2Y(12) inhibitor","volume":"14","author":"Htun","year":"2013","journal-title":"Expert Opin. Pharmacother."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:12:20Z","timestamp":1728346340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224003915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":48,"alternative-id":["S0006295224003915"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116408","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116408"}}